2024-05-10T11:58:01-05:00 2023-06-30 814234542 BPM LLP 4200 BOHANNON DRIVE SUITE 250 MENLO PARK CA 940251021 990 2022-07-01 453266802 CANCER COMMONS CANC 6502894044 2625 MIDDLEFIELD ROAD SUITE 104 PALO ALTO CA 94306 JAY M TENENBAUM PRESIDENT, CHAIRMAN, AND DIRECTOR 6502894044 2024-05-09 1 JAY TENENBAUM 999009999 0 TAMARA L MCINERNEY P00011797 6508556800 2024-05-09 2 AAL1 IAL1 2022 2023-04-26 12:10:37Z X JAY M TENENBAUM 2625 MIDDLEFIELD ROAD SUITE 104 PALO ALTO CA 94306 1332246 0 X WWW.CANCERCOMMONS.ORG X 2011 CA CANCER COMMONS BRINGS TOGETHER A TEAM OF EXPERTS, WHO COMBINE COMPASSION WITH SCIENTIFIC KNOWLEDGE TO HELP PATIENTS UNDERSTAND THEIR DISEASE AND ACCESS THEIR BEST TREATMENT OPTIONS. EACH PATIENT IS CONNECTED TO A TEAM, CONSISTING OF NURSE NAVIGATORS, PHD SCIENTISTS, PHYSICIANS, AND NATIONAL EXPERTS, WHO, REVIEW THE PATIENT'S MEDICAL HISTORY, RESEARCH ADDITIONAL TESTING THAT COULD IMPACT THE PATIENT'S TREATMENT PLAN, IDENTIFY CLINICAL TRIAL OPTIONS AVAILABLE FOR THE PATIENT, INVESTIGATE ACCESS TO NEW OFF-LABEL TREATMENTS, AS WELL AS OBTAIN KEY INSIGHTS FROM CANCER EXPERTS THROUGH VIRTUAL TUMOR BOARDS. CANCER COMMONS' GOAL IS TO EQUIP PATIENTS WITH THE KNOWLEDGE THEY NEED TO BE ABLE TO CHOOSE THEIR BEST PLAN OF ACTION AT NO COST TO THE PATIENT. 7 7 18 16 0 0 1629264 1170687 25733 58820 361 2704 0 -67867 1655358 1164344 43680 0 0 0 1139490 1207447 0 0 150994 453010 375398 1636180 1582845 19178 -418501 832926 408611 62826 57012 770100 351599 X CANCER COMMONS BRINGS TOGETHER A TEAM OF EXPERTS, WHO COMBINE COMPASSION WITH SCIENTIFIC KNOWLEDGE TO HELP PATIENTS UNDERSTAND THEIR DISEASE AND ACCESS THEIR BEST TREATMENT OPTIONS. 0 0 1260398 58820 SEE SCHEDULE O 1260398 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 8 0 1 18 1 0 0 0 0 0 0 0 0 0 0 0 0 X 7 7 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 CA X MARTHA DEHNOW 6505303636 2625 MIDDLEFIELD ROAD SUITE 104 PALO ALTO CA 94306 X PAUL BILLINGS BOARD MEMBER 1.00 X 0 0 0 GLADYS MONROY BOARD MEMBER 1.00 X 0 0 0 LAURENCE MARTON BOARD MEMBER 2.00 X 0 0 0 VERN NORVIEL BOARD MEMBER 1.00 X 0 0 0 ED STAREN BOARD MEMBER 1.00 X 0 0 0 JAY M TENENBAUM PRESIDENT 20.00 X X 0 0 0 DAVID DALY BOARD MEMBER (THRU 12/22) 1.00 X 0 0 0 MASAKO DUBOIS SECRETARY 40.00 X 102000 0 7782 SHELLEY FRISBIE CFO 40.00 X 180000 0 0 REBECCA DRISCOLL CEO 40.00 X 100000 0 6993 KAUMUDI BHAWE SCIENTIST 40.00 X 140500 0 25398 DEBORAH CHRISTENSEN PATIENT NAVIGATOR 40.00 X 136250 0 18570 EMILYA SHTIVELMAN SENIOR SCIENTIST 25.00 X 154938 0 332 813688 0 59075 5 0 1 0 THE SHELLARD GROUP 1325 HOWARD AVE 944 BURLINGAME CA 94010 CFO AND COO SERVICES 180000 EMILYA SHTIVELMAN 1040 FILBERT STREET SAN FRANCISCO CA 94133 SCIENTIFIC CONSULTING 108660 2 66409 1104278 105314 1170687 PROGRAM SERVICE FEES 900099 58820 58820 58820 24 24 102715 100035 2680 2680 2680 0 66409 67867 -67867 -67867 1164344 58820 0 -65163 X 354396 265517 44719 44160 686133 609821 29244 47068 101106 79263 9293 12550 65812 57343 2871 5598 1912 1912 80010 16334 44785 18891 240289 218003 15050 7236 22788 1055 9963 11770 12071 2093 6471 3507 14856 6193 8663 MKT AND BUS DEV 4890 4676 214 FACILITIES & EQUIPMENT1 2351 100 2251 OTHER COSTS -3769 -3769 1582845 1260398 171453 150994 419572 134178 400000 255352 11354 17081 6828 6828 0 0 2000 2000 832926 408611 62826 57012 62826 57012 X 590204 329703 179896 21896 770100 351599 832926 408611 -418501 0 X 0 0 0 X 1802396 2103518 1733265 1629264 1170687 8439130 1802396 2103518 1733265 1629264 1170687 8439130 3339589 5099541 361 23 384 2500 868 6329 322 10019 8449533 84553 0.60350 0.54830 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 6828 6828 0 0 EVENT #1 66409 66409 34098 33769 66409 66409 34098 33769 67867 -67867 X X X 0 0 0 0 0 0 0 1 0 SHELLEY FRISBIE CFO 180000 0 0 0 0 0 0 0 0 0 180000 0 0 0 KAUMUDI BHAWE SCIENTIST 140000 0 500 0 0 0 0 0 25398 0 165898 0 0 0 EMILYA SHTIVELMAN SENIOR SCIENTIST 152938 0 2000 0 0 0 0 0 332 0 155270 0 0 0 DEBORAH CHRISTENSEN PATIENT NAVIGATOR 133750 0 2500 0 0 0 0 0 18570 0 154820 0 0 0 PART I, LINE 7 BONUSES ARE APPROVED BY MANAGEMENT AND THE BOARD OF DIRECTORS. X 1 100035 FMV X VIDEO PRODUCTION 1 4700 FMV X AIRFARE 1 308 FMV X SUPPLIES 1 271 FMV 0 0 0 PART I, COLUMN (B): THE ORGANIZATION IS REPORTING THE NUMBER OF CONTRIBUTORS. FORM 990, PART III, LINE 4A: CANCER COMMONS BRINGS TOGETHER A TEAM OF PATIENT NAVIGATORS, PHD SCIENTISTS, PHYSICIANS, AND NATIONAL EXPERTS, WHO COMBINE COMPASSION WITH DEEP SCIENTIFIC KNOWLEDGE TO HELP PATIENTS UNDERSTAND THEIR DISEASE AND ACCESS THEIR BEST TREATMENT OPTIONS. CANCER TYPE - CANCER COMMONS ASSISTS PATIENTS, PARTICULARLY THOSE WITH METASTASIS AND LATE-STAGE DISEASE, WITH ANY CANCER TYPE, INCLUDING, BUT NOT LIMITED TO, BRAIN, PANCREATIC, COLORECTAL, ESOPHAGEAL, OVARIAN, BREAST, LUNG, AND PROSTATE CANCERS. ACCOMPLISHMENTS INCLUDE: FURTHER ENHANCEMENT OF NAVIGATION SERVICES, INCLUDING HELP WITH REGISTRATION, IDENTIFYING PATIENT NEEDS INCLUDING GOALS OF TREATMENT, AND ASSISTING PATIENTS AND CAREGIVERS IN COLLECTING MEDICAL RECORDS. CONTINUATION OF THE VIRTUAL TUMOR BOARD ("VTB") FOR PANCREATIC AND BRAIN PATIENTS. A VTB IS A NETWORK OF EXPERT ONCOLOGISTS AND CLINICAL SCIENTISTS WHO REVIEW INDIVIDUAL CANCER PATIENTS' CASES AND PROVIDE DETAILED TREATMENT OPTIONS REPORTS FOR THE PATIENTS TO SHARE WITH THEIR ONCOLOGISTS AND MEDICAL TEAMS. CONTINUATION OF THE FINAL TWO QUARTERLY WEBINARS OF THE PAT LOONEY EDUCATIONAL SERIES FOR CLIENT EMPOWERMENT AND POSTING AND PUBLISHING OF EDUCATIONAL ARTICLES - TO INFORM PATIENTS OF THE LATEST ADVANCEMENTS IN THE FIELD OF PRECISION ONCOLOGY AND INFORMATION PERTINENT TO THE CANCER IMPACTED COMMUNITY. EXPANDED THE LEARNING HEALTH SYSTEM BRAIN PILOT INTO AN ACTIVE BRAIN CANCER LEARNING HEALTH SYSTEM. THIS INITIATIVE WILL BE REPLICATED IN PANCREATIC AND OTHER CANCERS DURING FY24. FEE FOR SERVICE: THE ORGANIZATION CONTINUED OFFERING ENHANCED SERVICES PROGRAMS THIS FISCAL YEAR TO PROVIDE A CONTINUUM OF CARE AND SERVICES BEYOND THOSE CUSTOMARILY PROVIDED AT NO CHARGE. CANCER COMMONS PLUS IS A SUBSCRIPTION PROGRAM THAT PROVIDES MONTHLY OR QUARTERLY OUTREACH TO PATIENTS/CAREGIVERS TO ASSESS PROGRESS, OFFER ASSISTANCE, ADDRESS QUESTIONS/CONCERNS, DISCUSS DEVELOPMENTS WITH TREATMENT, AND HELP PATIENTS PLAN AHEAD. CLINICAL TRIALS AND EXPANDED ACCESS ASSISTANCE PROVIDES NAVIGATION, MANAGEMENT OF THE TRIAL/TREATMENT OPTIONS LIST, COMMUNICATION AND COORDINATION WITH TRIAL SITE(S), AND ASSISTANCE WITH THE APPLICATION PROCESS, ALL BASED ON CLIENT/CAREGIVER PRIORITIES AND GOALS. PARTNERSHIP WITH XCURES - CANCER COMMONS PATIENTS ARE INVITED TO ENROLL IN XCELSIOR, A PATIENT- CENTRIC PLATFORM TRIAL FOR PRECISION ONCOLOGY, THAT CANCER COMMONS IS PARTICIPATING IN WITH TECHNOLOGY PARTNER XCURES. OTHER PARTNERSHIPS - CANCER COMMONS HAS PARTNERSHIPS WITH OTHER ORGANIZATIONS AND INSTITUTIONS WHO SHARE THE CANCER COMMONS PATIENT-CENTRIC PHILOSOPHY. THESE ORGANIZATIONS REFER PATIENTS WITH CHALLENGING CASES OR OFFER THEIR SERVICES TO CANCER COMMONS' PATIENTS. THE MOST ACTIVE PARTNERS DURING FISCAL YEAR 2023 ARE THE PANCREATIC CANCER ACTION NETWORK (PANCAN) AND THE MUSELLA FOUNDATION FOR BRAIN TUMOR RESEARCH & INFORMATION. BOTH ORGANIZATIONS PROVIDED GRANT FUNDING TO CANCER COMMONS FOR FISCAL YEAR ENDED JUNE 30, 2022, AND THOSE PROJECTS WERE COMPLETED IN FY23. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS GIVEN TO THE GOVERNING BODY BEFORE THE RETURN IS FILED. THEY REVIEW AND CAN REQUEST CHANGES AT THIS TIME. FORM 990, PART VI, SECTION B, LINE 12C THE OFFICERS, DIRECTORS AND KEY EMPLOYEES ARE REQUIRED TO REVIEW AND SIGN THE WRITTEN CONFLICT OF INTEREST POLICY ANNUALLY. FORM 990, PART VI, SECTION B, LINE 15 THE BOARD OF DIRECTORS PERFORMS ALL INTERVIEWS SPECIFIC TO TOP KEY POSITIONS WHICH IS THEN FORWARDED TO THE FULL BOARD OF DIRECTORS FOR REVIEW AND APPROVAL. FORM 990, PART VI, SECTION C, LINE 19 MADE AVAILABLE UPON REQUEST. FORM 990, PART VII, SECTION B, LINE 1: EMILYA SHTIVELMAN'S COMPENSATION REPORTED ON PART VII, SECTION B IS INCLUDED IN THE AMOUNTS ON PART VII, SECTION A. FORM 990, PART IX, LINE 11G OTHER CONSULTING COSTS: PROGRAM SERVICE EXPENSES 218,003. MANAGEMENT AND GENERAL EXPENSES 15,050. FUNDRAISING EXPENSES 7,236. TOTAL EXPENSES 240,289.